North America Intravenous Immunoglobulin Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Size and Forecast (2020-2030), North America and Country Share, Trend, and Growth Opportunity Analysis Coverage: Type (IgG, IgA, IgM, and Others), Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Thrombocytopenic Purpura, Multifocal Motor Neuropathy, Hypogammaglobulinemia, Guillain-Barre Syndrome, Specific Antibody Deficiency, Inflammatory Myopathies, Myasthenia Gravis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Country (US, Canada, and Mexico)

No. of Pages: 107    |    Report Code: BMIRE00027592    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Intravenous Immunoglobulin Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Intravenous Immunoglobulin Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Intravenous Immunoglobulin Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increase in immunodeficiency disorders
  • 5.1.2 Growing demand for intravenous immunoglobulin therapies
5.2 Market Opportunities
  • 5.2.1 Expansion in immunotherapy market
  • 5.2.2 Growth in personalized intravenous immunoglobulin therapies
5.3 Future Trends
  • 5.3.1 Advances in immunoglobulin replacement therapies
  • 5.3.2 Increasing adoption of subcutaneous immunoglobulin treatments
5.4 Impact of Drivers and Restraints

6. North America Intravenous Immunoglobulin Market Regional Analysis

6.1 North America Intravenous Immunoglobulin Market Overview
6.2 North America Intravenous Immunoglobulin Market Revenue 2020-2030 (US$ Million)
6.3 North America Intravenous Immunoglobulin Market Forecast Analysis

7. North America Intravenous Immunoglobulin Market Analysis – by Type

7.1 IgG
  • 7.1.1 Overview
  • 7.1.2 IgG: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2031 (US$ Million)
7.2 IgA
  • 7.2.1 Overview
  • 7.2.2 IgA: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2031 (US$ Million)
7.3 IgM
  • 7.3.1 Overview
  • 7.3.2 IgM: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Intravenous Immunoglobulin Market Analysis – by Application

8.1 Immunodeficiency Diseases
  • 8.1.1 Overview
  • 8.1.2 Immunodeficiency Diseases: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Chronic Inflammatory Demyelinating Polyneuropathy
  • 8.2.1 Overview
  • 8.2.2 Chronic Inflammatory Demyelinating Polyneuropathy: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Idiopathic Thrombocytopenic Purpura
  • 8.3.1 Overview
  • 8.3.2 Idiopathic Thrombocytopenic Purpura: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Multifocal Motor Neuropathy
  • 8.4.1 Overview
  • 8.4.2 Multifocal Motor Neuropathy: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Hypogammaglobulinemia
  • 8.5.1 Overview
  • 8.5.2 Hypogammaglobulinemia: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Guillain-Barre Syndrome
  • 8.6.1 Overview
  • 8.6.2 Guillain-Barre Syndrome: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Specific Antibody Deficiency
  • 8.7.1 Overview
  • 8.7.2 Specific Antibody Deficiency: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Inflammatory Myopathies
  • 8.8.1 Overview
  • 8.8.2 Inflammatory Myopathies: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Myasthenia Gravis
  • 8.9.1 Overview
  • 8.9.2 Myasthenia Gravis: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)

9. North America Intravenous Immunoglobulin Market Analysis – by Distribution Channel

9.1 Hospital Pharmacy
  • 9.1.1 Overview
  • 9.1.2 Myasthenia Gravis: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacy
  • 9.2.1 Overview
  • 9.2.2 Myasthenia Gravis: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)

10. North America Intravenous Immunoglobulin Market – North America Analysis

10.1 North America
  • 10.1.1 North America Intravenous Immunoglobulin Market Breakdown, by Key Country, 2023 and 2030 (%)
  • 10.1.1.1 North America Intravenous Immunoglobulin Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.1.1 US: North America Intravenous Immunoglobulin Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Intravenous Immunoglobulin Market Breakdown, by Application
    • 10.1.1.1.3 US: North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel
  • 10.1.1.2 Canada: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.2.1 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Application
    • 10.1.1.2.3 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel
  • 10.1.1.3 Mexico : North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Application
    • 10.1.1.3.3 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Intravenous Immunoglobulin Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Takeda Pharmaceutical Co Ltd
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Grifols SA
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Pfizer Inc
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 ADMA Biologics, Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Octapharma AG
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Kedrion SpA
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 CSL Ltd
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 LFB Group
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Prothya Biosolutions B.V
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Intravenous Immunoglobulin Market

  1. Takeda Pharmaceutical Co Ltd
  2. Grifols SA
  3. Pfizer Inc
  4. ADMA Biologics, Inc
  5. Bio Products Laboratory Ltd
  6. Octapharma AG
  7. Kedrion SpA
  8. CSL Ltd
  9. LFB Group
  10. Prothya Biosolutions B.V
north-america-intravenous-immunoglobulin-market